Table 2.
Matrix of pairwise comparison among hypoglycemic drugs on MMSE score (shown as mean difference and 95% confidence intervals).
| DPP-4 | ITSN20 | PLZ | GLP-1 | MTN | Placebo | |
|---|---|---|---|---|---|---|
| SUCRA (%) | 100 | 65.1 | 62 | 44.8 | 22.6 | 5.5 |
| DPP-4 | 0 | −2.97 (−3.70, −2.24) | −2.83(−4.52, −1.14) | −3.33 (−4.28, −2.38) | −3.78 (−4.78, −2.78) | −4.08 (−4.77, −3.39) |
| ITSN20 | 2.97 (2.24, 3.70) | 0 | 0.14 (−1.42, 1.70) | −0.36 (−1.06, 0.34) | −0.81 (−1.57, −0.05) | −1.11 (−1.35, −0.87) |
| PLZ | 2.83 (1.14, 4.52) | −0.14 (−1.70, 1.42) | 0 | −0.50 (−2.18, 1.17) | −0.95 (−2.65, 0.75) | −1.25 (−2.79, 0.29) |
| GLP-1 | 3.33 (2.38, 4.28) | 0.36(−0.34, 1.06) | 0.50 (−1.17, 2.18) | 0 | −0.45 (−1.43, 0.53) | −0.75 (−1.41, −0.09) |
| MTN | 3.78 (2.78, 4.78) | 0.81 (0.05, 1.57) | 0.95 (−0.75, 2.65) | 0.45 (−0.53, 1.43) | 0 | −0.30 (−1.02, 0.42) |
| Placebo | 4.08 (3.39, 4.77) | 1.11 (0.87, 1.35) | 1.25 (−0.29, 2.79) | 0.75 (0.09, 1.41) | 0.30 (−0.42, 1.02) | 0 |
SUCRA, Surface under the cumulative ranking curve; ITSN20, Intranasal insulin 20IU; MTN, Metformin; PLZ, Pioglitazone;, RLZ2, Rosiglitazone 2 mg; RLZ4, Rosiglitazone 4 mg; RLZ8, Rosiglitazone 8mg; RLZ10, Rosiglitazone 10 mg; GLP-1, Glucagon-like Peptide-1; DPP-4, Dipeptidyl Peptidase 4 Inhibitor; MMSE, Mini-mental State Examination.